Recon: Sangamo Lands $3B Gene Editing Deal with Gilead; CDC Advisers Say Nasal Flu Vaccine Can Come Back

• Sangamo in $3 billion gene-editing deal with Gilead (Reuters) (Xconomy) (Press)
• Bristol-Myers axes 107 more staffers as it completes an R&D overhaul (Endpoints)
• Pharma's $50 billion tax windfall for investors (Axios)
• States Work to Curb Drug Spending (Pew)
• Middlemen Play Gatekeeper in Battle to Curb Soaring Drug Costs (Bloomberg)
• The myth of what’s driving the opioid crisis (Politico)
• 3 Ways FDA can facilitate claims of biosimilar interchangeability (Avalere)
• FDA clears Access Vascular’s HydroPICC catheter (MassDevice)
• FluMist nasal flu vaccine can come back, advisers say (NBC News) (BioCentury) (Reuters)
• FDA Rolling Out Updates to UDI Database in 2018 (Emergo)

• ‘It’s breathtaking’: A Chinese biotech CEO weighs in on policy changes remaking China’s FDA (STAT)
• Australia legislates lower drug prices (BioCentury)
• Letter of support for intermediate Age Related Macular Degeneration (AMD) biomarker and novel clinical endpoint development (EMA)
• Statement on medicines and medical devices safety review (UK Parliament)
• Aquilon Medical Nebulisers: people urged to stop use immediately (MHRA)
• Richter Expects Esmya Sales To Drop 50% Following EU Restrictions Over Liver Concerns (Scrip-$)
• EFPIA and ICHOM form a Strategic Alliance Partnership to Foster Commitment to Outcomes Measurement as a Means of Driving Value in Health Care (EFPIA)

• Novo Nordisk prepares to swallow its rivals for breakfast (EP Vantage) (CNBC)
• Forecasts of genetic fate just got a lot more accurate (MIT Technology Review)
• Takeda Catches Rising Tide Of Antisense Neuroscience R&D (Scrip-$)
• Regeneron vision drug Eylea sees upward tick in unexplained side-effect cases (Fierce)
• Rite Aid's PBM Becomes More Attractive Under Albertsons (Forbes)
• AMBER Partners with Multi-National Healthcare Company to Create Global 3D Bioprinting Collaborative (Press)
• Achillion Announces Restructuring to Advance Corporate Strategy; Announces 2017 Fourth Quarter and Full Year Financial Results (Press)
•  ImmunoCellular Therapeutics Announces Review of Strategic Alternatives (Press)
• WuXi STA and Regulus Announce microRNA Development and Manufacturing Collaboration (Press)

• Bluebird bio details plans to file three blockbusters (pharmaphorum)
• AbbVie fibroids drug meets Phase 3 endpoint (BioPharma Dive)
• Cannabis Company GW Pharmaceuticals’ Seizure Drug Flunks Phase II Trial (BioSpace) (EP Vantage)
• Europe Approves JHL Biotech's Clinical Trial Application for Bevacizumab Biosimilar to Affordably Treat Colorectal, Lung, and Ovarian Cancers (Press)
• Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease (Press)
• Daiichi Sankyo Initiates Phase 1 Study of DS-1062 in Patients with Advanced Non-Small Cell Lung Cancer (Press)
• Xencor Doses First Patient in Phase 1 Study of XmAb 18087 Bispecific Tumor Targeting Antibody for the Treatment of Neuroendocrine Tumors and Gastrointestinal Stromal Tumors (Press)
• Apellis Pharmaceuticals Announces 18-Month Results of Phase 2 Study (FILLY) of APL-2 in Geographic Atrophy (Press)

• Cognoa Hits Major Milestone Towards First AI-Based Autism Diagnostic (Press)
• FDA Clears GOKnee3D MRI Application from Siemens Healthineers (Press)
• RenovaCare touts win in patent spat with Avita Medical (MassDevice)
• B. Braun subsidiary completes acquisition of California firm (The Morning Call)
• Leaked Nokia memo says no path forward for ‘struggling’ digital health business (The Verge)
• MiMedx, Fast-Growing Developer of Tissue Graft Products, Didn’t Report Payments to Doctors (The Wall Street Journal)
• Why you should be 3D printing your medical devices (PlasticsToday)
• FDA removed 10% of medtech establishments from its registration database: Here’s why (Medical Design & Outsourcing)

• US FDA Advisory Cmte. Review Of Charleston's Hydexor Exposes Flaws In Commercial Strategy (Scrip-$)
• IPAB RIP (Health Affairs)
• Lawmakers, government target actions, plan hearings to address opioids (S&P Global)
• Idaho is ignoring Obamacare rules. That could set off a catastrophic chain reaction (Vox)
• Pew, HIMSS press ONC to modify planned trusted exchange framework to ensure interoperability (HealthcareITNews)
• Practice Fusion is scrapping free software model after agreeing to sell to Allscripts (CNBC)
• Philips launches FocusPoint, an intuitive web-based application to help reduce costs and improve operational efficiencies (Press)

• FDA Advisory Committee Calendar

• Review launched to respond to patient concerns about NHS treatments (UK Gov)
• Sanofi taps clinical site network in UK partnership (Outsourcing-Pharma)
• Brain cancer research to receive £45 million funding (UK Gov)

• Health ministry constitutes DTAB sub-committee to re-examine banned 344 FDC drugs (PharmaBiz)
• NPPA report underscores inadequacy of DPCO in tackling overcharging by hospitals (PharmaBiz)

• Australia legislates lower drug prices (BioCentury)

• Tandem Diabetes bids for Health Canada nod (Drug Delivery Business News)

• Benzodiazepines: our other prescription drug epidemic (Stat)
• How Value-Based Medicare Payments Exacerbate Health Care Disparities (JAMA)
• Cerner Implements Surescripts Prescription Price Transparency Functionality Within the EHR (Press)